EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)

Yan-Song Lin iD, Ren-Fei Wang, Rui Huang, Qiang Wen, Wei Cao, Li-Bo Chen, Ye Guo, Xiao-Rong Hou, Li Li, Xiao-Yi Li, Cheng-He Lin, Zhi-Yan Liu und 8 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025-08 · 52 (10) · 3859-3876

DOI: 10.1007/s00259-025-07222-1 ↗

Kurz gefasst

Leitlinie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 25.03.2025. Verfasst von Yan-Song Lin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,…. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) has become a challenge in clinical practice, particularly in China with a high incidence and undesirable survival outcome. Since the publication of first China consensus on the diagnosis and treatment of RAIR-DTC in 2019, significant and rapid advances have occurred in the field both in China and internationally. This guideline aims to inform Chinese clinicians, researchers, patients, and health policy makers on the latest evidence and recommendations, to further standardize the clinical diagnosis and treatment of RAIR-DTC. METHODS: The structured clinical questions addressed in this guideline were derived from clinical diagnostic and treatment processes, with references to study, prior guidelines, expert consensus, and systematic reviews, etc. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used for quantitative and qualitative evaluation of the evidence. The editorial process was completely independent of the guideline development group. RESULTS: The guideline addressed 26 clinical questions and formed 35 recommendations. In this guideline, the definition criteria for RAIR-DTC was optimized, prediction and identification was based on evidence including molecular testing, dynamic biochemical changes, and multimodal imaging. Comprehensive pre-treatment clinical evaluation was emphasized and tailored for individualized decision-making. The combination of systematic therapy and surgery, and the redifferentiation followed by RAI therapy were also reviewed and updated. Molecular imaging plays a unique role in the pre-assessing and therapeutic response evaluation for RAIR-DTC. CONCLUSIONS: We have updated and developed evidence-based recommendations with the aim of providing scientific, rigorous, and comprehensive guidance for the clinical diagnosis and treatment of RAIR-DTC patients in China. We hope to share our guideline with colleagues out of China, with the expectation of further comments and suggestions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsHumansChinaEast Asian People

Stichwörter der Autor:innen

Chinese Society of Nuclear Medicine (CSNM)Committee Chinese Society of Clinical Oncology (CSCO)GuidelineRadioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC)Thyroid oncology committee of China Anti-Cancer Association (CACA)

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. linyansong1968@163.com.
  • Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
  • Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  • Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China.
  • Department of Nuclear Medicine, Hubei Province Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University Science and Technology, Wuhan, Hubei, China.
  • Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Yan-Song Lin

Förderung

  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Lin, Y. S., Wang, R. F., Huang, R., Wen, Q., Cao, W., Chen, L. B., Guo, Y., Hou, X. R., Li, L., Li, X. Y., Lin, C. H., Liu, Z. Y., Wang, H., Wang, X. F., Wang, Z. Y., Wu, X. H., Xu, S. H., Yang, A. M., Zhang, B., & Zhang, Y. L. (2025). Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition). European Journal of Nuclear Medicine and Molecular Imaging, 52(10), 3859-3876. https://doi.org/10.1007/s00259-025-07222-1

Vancouver

Lin YS, Wang RF, Huang R, Wen Q, Cao W, Chen LB, et al. Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition). European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(10):3859-3876. doi:10.1007/s00259-025-07222-1

BibTeX
@article{Lin2025,
  author = {Lin, Yan-Song and Wang, Ren-Fei and Huang, Rui and Wen, Qiang and Cao, Wei and Chen, Li-Bo and Guo, Ye and Hou, Xiao-Rong and Li, Li and Li, Xiao-Yi and Lin, Cheng-He and Liu, Zhi-Yan and Wang, Hao and Wang, Xu-Fu and Wang, Zhuo-Ying and Wu, Xiao-Hong and Xu, Shu-Hang and Yang, Ai-Min and Zhang, Bo and Zhang, Yue-Lun},
  title = {Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {10},
  pages = {3859--3876},
  doi = {10.1007/s00259-025-07222-1}
}
Kostenlos starten →